Business Context and Reporting Period
This Form 8-K Current Report from Biomerica, Inc. (BMRA) covers events occurring on June 4, 2025, with the report filed on June 6, 2025. The filing primarily addresses changes to the Company's Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes.
Material Changes
- Director Departure: Ms. Cathy Coste stepped down as a member of the Board of Directors effective June 4, 2025. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: Mr. Eric Chin was appointed as an independent member of the Board effective June 4, 2025, filling the vacancy left by Ms. Coste.
- Committee Roles: Mr. Chin has been designated as an independent director and an "audit committee financial expert." He will serve as Chairperson of the Audit Committee and as a member of the Nominating and Corporate Governance Committee and the Compensation Committee.
Compensation and Management Commentary
In connection with his appointment, Mr. Chin will receive the following compensation:
- Cash Fee: An annualized cash fee of $41,000, paid quarterly.
- Equity Compensation: 10,000 Restricted Shares under the 2024 Stock Incentive Plan.
- Vesting Schedule: The Restricted Shares will "cliff vest" 100% on December 12, 2025.
Mr. Chin brings significant financial experience, having served as CFO of Akido Labs (since 2023) and Astrana Health (2018–2022), and previously held finance roles at Public Storage and Alexandria Real Estate Equities, Inc. He is a Certified Public Accountant.
Investor Verification Checklist
- Verify the independence status of Mr. Eric Chin under Nasdaq Rule 5605.
- Confirm the vesting terms and potential dilution impact of the 10,000 Restricted Shares granted to Mr. Chin.
- Review the composition of the Audit Committee to ensure compliance with regulatory requirements following the leadership change.
- Check for any subsequent filings regarding the resignation of Ms. Coste to ensure no undisclosed conflicts arose.